Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today Roy J. Wu, MBA, Senior Vice President for Global Business Development, will present a corporate update and clinical data for the company’s lead small molecule drugs at the BIO International Convention 2026, June 22-25, in San Diego.
Mr. Wu’s presentation will be June 22, at 4:30 pm, in Theater 1 of the BIO Business Forum. He also will be available for meetings through the BIO Partnering program.
Lingodlinurad (ABP-671), a novel URAT1 inhibitor, is positioned as monotherapy for patients with chronic gout, as well as in combination with allopurinol for refractory gout. . The recently completed Phase 2b portion of Atom’s global Phase 2b/3 trials demonstrated significant efficacy in reducing sUA to < 6 mg, with a higher proportion of patients experiencing levels < 5 mg/dL and 4 mg/dL. The study showed good safety and tolerability. One Phase 3 trial is under way in China with two multi-country Phase 3 studies launching this year.
For Atom’s anti-inflammatory, ABP-745, minimal adverse events were reported in early trials, with high bioavailability and exposure, potentially leading to greater therapeutic efficacy for acute gout flares as well as atherosclerotic diseases. The Phase 2 trial for acute gout is comparing ABP-745 to placebo and colchicine, a standard treatment for acute gout and top line data readout is expected in August this year. A multi-country Phase 2 trial of ABP-745 for ASCVD was launched in April 2026 and data readout is expected in Q4/2027.
Atom also is planning to launch Phase 2 trials of ABP-745 for other heart-related indications, including pericarditis and heart failure.
About Atom Therapeutics
Atom Therapeutics Co., Ltd is a fast-growing innovative clinical stage biotechnology company focused on development of novel therapies for metabolic, inflammatory, and cardiovascular diseases. The company’s lead product, ABP-671, is currently undergoing Phase 3 clinical trials in China and globally. It is being developed for the treatment of chronic gout, hyperuricemia, tophaceous gout, and refractory gout. Another small molecule ABP-745 for anti-inflammatory and autoimmune conditions. Its global multicenter Phase 2 clinical trial for treatment of acute gout is nearing completion, while a global multicenter Phase 2 study for atherosclerosis is currently ongoing. In addition, Phase 2 clinical trials of ABP-745 are planned for indications including pericarditis and heart failure. For more information, visit: www.atomthera.com or atomthera.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615894701/en/
Media gallery
